A 24-wk randomised, double-blind, multi-centre, active-controlled (pioglitazone) study to evaluate the efficacy, safety & tolerability of tesaglitazar therapy when administered to patients with type 2 diabetes

Trial Profile

A 24-wk randomised, double-blind, multi-centre, active-controlled (pioglitazone) study to evaluate the efficacy, safety & tolerability of tesaglitazar therapy when administered to patients with type 2 diabetes

Discontinued
Phase of Trial: Phase III

Latest Information Update: 18 Nov 2010

At a glance

  • Drugs Pioglitazone; Tesaglitazar
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Acronyms GALLANT-6
  • Sponsors AstraZeneca
  • Most Recent Events

    • 09 Aug 2006 Status change
    • 11 Dec 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top